Top

Published in:

01-01-2014 | Valvular Heart Disease (V Nkomo, Section Editor)

Clinical Implications of Conduction Abnormalities and Arrhythmias After Transcatheter Aortic Valve Implantation

Authors: Robert M. A. van der Boon, Patrick Houthuizen, Rutger-Jan Nuis, Nicolas M. van Mieghem, Frits Prinzen, Peter P. T. de Jaegere

Published in: Current Cardiology Reports | Issue 1/2014

Abstract

Transcatheter aortic valve implantation (TAVI) has become an established treatment option for patients with aortic stenosis at prohibitive risk to undergo surgical aortic valve replacement. Despite conveying obvious clinical benefits and a decreasing frequency of complications, the occurrence of new conduction abnormalities and arrhythmias remains an important issue. Generally considered a minor complication, they may have a profound impact on prognosis and quality of life after TAVI. Therefore the purpose of this review is to assess and discuss the available information on clinical implications of both new conduction abnormalities and arrhythmias after TAVI.

1.••

Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). G Ital Cardiol (Rome). 2013;14(3):167–214. The latest version of the European Guidelines on the management of valvular heart disease, including a therapeutic algorithm.

2.••

Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597–607. Randomized controlled trial showing that TAVI is superior to medical treatment in patients at prohibitive risk to undergo SAVR.PubMedCrossRef

Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012;366(18):1696–704.PubMedCrossRef

4.••

Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187–98. Randomized controlled trial comparing outcome between TAVI and SAVR in patients at high operative risk.PubMedCrossRef

Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366(18):1686–95.PubMedCrossRef

6.•

Houthuizen P, Van Garsse LAFM, Poels TT, de Jaegere P, van der Boon RMA, Swinkels BM, et al. Left bundle-branch block induced by transcatheter aortic valve implantation increases risk of death. Circulation. 2012;126(6):720–8. Observational study comparing outcome during follow-up between patients with and without LBBB after TAVI.PubMedCrossRef

7.•

Urena M, Mok M, Serra V, Dumont E, Nombela-Franco L, DeLarochellière R, et al. Predictive factors and long-term clinical consequences of persistent left bundle branch block following transcatheter aortic valve implantation with a balloon-expandable valve. J Am Coll Cardiol. 2012;60(18):1743–52. Observational study assessing the persistency of LBBB during follow-up and comparing outcomes in patients with and without LBBB.PubMedCrossRef

8.•

Testa L, Latib A, De Marco F, De Carlo M, Agnifili M, Latini RA, et al. Clinical impact of persistent left bundle-branch block after transcatheter aortic valve implantation with CoreValve Revalving System. Circulation. 2013;127(12):1300–7. Observational registry from Italy assessing the effects of LBBB on outcome after TAVI with the MCS.PubMedCrossRef

9.••

Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol. 2012;60(15):1438–54. Updated guidelines on reporting of outcomes after TAVI including new conduction abnormalities.PubMedCrossRef

10.•

van der Boon RM, Nuis R-J, Van Mieghem NM, Jordaens L, Rodés-Cabau J, van Domburg RT, et al. New conduction abnormalities after TAVI–frequency and causes. Nat Rev Cardiol. 2012;9(8):454–63. Comprehensive review assessing anatomical-, device- and patient related factors influencing the occurence of new conduction abnormalities.

11.

Piazza N, Onuma Y, Jesserun E, Kint PP, Maugenest A-M, Anderson RH, et al. Early and persistent intraventricular conduction abnormalities and requirements for pacemaking after percutaneous replacement of the aortic valve. JACC Cardiovasc Interv. 2008;1(3):310–6.PubMedCrossRef

12.

Fraccaro C, Buja G, Tarantini G, Gasparetto V, Leoni L, Razzolini R, et al. Incidence, predictors, and outcome of conduction disorders after transcatheter self-expandable aortic valve implantation. Am J Cardiol. 2011;107(5):747–54.PubMedCrossRef

13.

Nuis R-J, Van Mieghem NM, Schultz CJ, Tzikas A, Van der Boon RM, Maugenest A-M, et al. Timing and potential mechanisms of new conduction abnormalities during the implantation of the Medtronic CoreValve System in patients with aortic stenosis. Eur Heart J. 2011;32(16):2067–74.PubMedCrossRef

14.

Zannad F, Huvelle E, Dickstein K, van Veldhuisen DJ, Stellbrink C, Køber L, et al. Left bundle branch block as a risk factor for progression to heart failure. Eur J Heart Fail. 2007;9(1):7–14.PubMedCrossRef

15.

Grines CL, Bashore TM, Boudoulas H, Olson S, Shafer P, Wooley CF. Functional abnormalities in isolated left bundle branch block. The effect of interventricular asynchrony. Circulation. 1989;79(4):845–53.PubMedCrossRef

16.

Lee S-J, McCulloch C, Mangat I, Foster E, De Marco T, Saxon LA. Isolated bundle branch block and left ventricular dysfunction. J Card Fail. 2003;9(2):87–92.PubMedCrossRef

17.

Vernooy K, Verbeek XAAM, Peschar M, Crijns HJGM, Arts T, Cornelussen RNM, et al. Left bundle branch block induces ventricular remodelling and functional septal hypoperfusion. Eur Heart J. 2005;26(1):91–8.PubMedCrossRef

18.

Tzikas A, van Dalen BM, Van Mieghem NM, Gutierrez-Chico J-L, Nuis R-J, Kauer F, et al. Frequency of conduction abnormalities after transcatheter aortic valve implantation with the Medtronic-CoreValve and the effect on left ventricular ejection fraction. Am J Cardiol. 2011;107(2):285–9.PubMedCrossRef

19.

Hoffmann R, Herpertz R, Lotfipour S, Aktug Ö, Brehmer K, Lehmacher W, et al. Impact of a new conduction defect after transcatheter aortic valve implantation on left ventricular function. JACC Cardiovasc Interv. 2012;5(12):1257–63.PubMedCrossRef

20.

Sinhal A, Altwegg L, Pasupati S, Humphries KH, Allard M, Martin P, et al. Atrioventricular block after transcatheter balloon expandable aortic valve implantation. JACC Cardiovasc Interv. 2008;1(3):305–9.PubMedCrossRef

21.

Bleiziffer S, Ruge H, Hörer J, Hutter A, Geisbüsch S, Brockmann G, et al. Predictors for new-onset complete heart block after transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2010;3(5):524–30.PubMedCrossRef

22.

Khawaja MZ, Rajani R, Cook A, Khavandi A, Moynagh A, Chowdhary S, et al. Permanent pacemaker insertion after CoreValve transcatheter aortic valve implantation: incidence and contributing factors (the UK CoreValve Collaborative). Circulation. 2011;123(9):951–60.PubMedCrossRef

23.

Jilaihawi H, Chin D, Vasa-Nicotera M, Jeilan M, Spyt T, Ng GA, et al. Predictors for permanent pacemaker requirement after transcatheter aortic valve implantation with the CoreValve bioprosthesis. Am Heart J. 2009;157(5):860–6.PubMedCrossRef

24.

Singh JP, Fan D, Heist EK, Alabiad CR, Taub C, Reddy V, et al. Left ventricular lead electrical delay predicts response to cardiac resynchronization therapy. Heart Rhythm. 2006;3(11):1285–92.PubMedCrossRef

25.

Sweeney MO, van Bommel RJ, Schalij MJ, Borleffs CJW, Hellkamp AS, Bax JJ. Analysis of ventricular activation using surface electrocardiography to predict left ventricular reverse volumetric remodeling during cardiac resynchronization therapy. Circulation. 2010;121(5):626–34.PubMedCrossRef

26.

Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140–50.PubMedCrossRef

27.

Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539–49.PubMedCrossRef

28.

Tang ASL, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363(25):2385–95.PubMedCrossRef

29.

Gold MR, Birgersdotter-Green U, Singh JP, Ellenbogen KA, Yu Y, Meyer TE, et al. The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy. Eur Heart J. 2011;32(20):2516–24.PubMedCrossRef

30.•

Reynolds MR, Magnuson EA, Lei Y, Wang K, Vilain K, Li H, et al. Cost-effectiveness of transcatheter aortic valve replacement compared with surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results of the PARTNER (Placement of Aortic Transcatheter Valves) trial (Cohort A). J Am Coll Cardiol. 2012;60(25):2683–92. Analysis from the PARTNER A Cohort demonstrating cost-effectiveness of TAVI compared with SAVR.

31.

Osnabrugge RLJ, Head SJ, Genders TSS, Van Mieghem NM, De Jaegere PPT, van der Boon RMA, et al. Costs of transcatheter versus surgical aortic valve replacement in intermediate-risk patients. Ann Thorac Surg. 2012;94(6):1954–60.PubMedCrossRef

32.

Buellesfeld L, Stortecky S, Heg D, Hausen S, Mueller R, Wenaweser P, et al. Impact of permanent pacemaker implantation on clinical outcome among patients undergoing transcatheter aortic valve implantation. J Am Coll Cardiol. 2012;60(6):493–501.PubMedCrossRef

33.

Houthuizen P, van der Boon RMA, Van Garsse LAFM, Prinzen FW, de Jaegere P. Why permanent pacemaker implantation after transcatheter aortic valve implantation does not affect long-term clinical outcome. J Am Coll Cardiol. 2012;60(22):2339–40. author reply 2340–2341.PubMedCrossRef

34.

Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA. 2002;288(24):3115–23.PubMedCrossRef

35.

Sweeney MO, Prinzen FW. A new paradigm for physiologic ventricular pacing. J Am Coll Cardiol. 2006;47(2):282–8.PubMedCrossRef

36.

Van der Boon RMA, Van Mieghem NM, Theuns DA, Nuis R-J, Nauta ST, Serruys PW, e.a. Pacemaker dependency after transcatheter aortic valve implantation with the self-expanding Medtronic CoreValve System. Int J Cardiol. 2013;168(2):1269–73.

37.

Simms AD, Hogarth AJ, Hudson EA, Worsnop VL, Blackman DJ, O’Regan DJ, e.a. Ongoing requirement for pacing post-transcatheter aortic valve implantation and surgical aortic valve replacement. Interact Cardiovasc Thorac Surg. 2013;17(2):328–33.

38.

Pereira E, Ferreira N, Caeiro D, Primo J, Adão L, Oliveira M, et al. Transcatheter aortic valve implantation and requirements of pacing over time. Pacing Clin Electrophysiol. 2013;36(5):559–69.PubMedCrossRef

39.

Moreno R, Dobarro D, López de Sá E, Prieto M, Morales C, Calvo Orbe L, et al. Cause of complete atrioventricular block after percutaneous aortic valve implantation: insights from a necropsy study. Circulation. 2009;120(5):e29–30.PubMedCrossRef

40.

Fraccaro C, Napodano M, Tarantini G. Conduction disorders in the setting of transcatheter aortic valve implantation: a clinical perspective. Catheter Cardiovasc Interv. 2013;81(7):1217–23.PubMedCrossRef

41.

Lévy S, Breithardt G, Campbell RW, Camm AJ, Daubert JC, Allessie M, et al. Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J. 1998;19(9):1294–320.PubMedCrossRef

42.

Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–5.PubMedCrossRef

43.

Webb JG, Altwegg L, Boone RH, Cheung A, Ye J, Lichtenstein S, et al. Transcatheter aortic valve implantation: impact on clinical and valve-related outcomes. Circulation. 2009;119(23):3009–16.PubMedCrossRef

44.

Buellesfeld L, Gerckens U, Schuler G, Bonan R, Kovac J, Serruys PW, et al. 2-year follow-up of patients undergoing transcatheter aortic valve implantation using a self-expanding valve prosthesis. J Am Coll Cardiol. 2011;57(16):1650–7.PubMedCrossRef

45.

Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol. 1997;30(4):1039–45.PubMedCrossRef

46.

Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946–52.PubMedCrossRef

47.

Stewart S, Hart CL, Hole DJ, McMurray JJV. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113(5):359–64.PubMedCrossRef

48.

Ngaage DL, Schaff HV, Barnes SA, Sundt 3rd TM, Mullany CJ, Dearani JA, et al. Prognostic implications of preoperative atrial fibrillation in patients undergoing aortic valve replacement: is there an argument for concomitant arrhythmia surgery? Ann Thorac Surg. 2006;82(4):1392–9.PubMedCrossRef

49.

Kalavrouziotis D, Buth KJ, Vyas T, Ali IS. Preoperative atrial fibrillation decreases event-free survival following cardiac surgery. Eur J Cardiothorac Surg. 2009;36(2):293–9.PubMedCrossRef

50.

Gaudino M, Andreotti F, Zamparelli R, Di Castelnuovo A, Nasso G, Burzotta F, et al. The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation. 2003;108 Suppl 1:II195–9.PubMed

51.•

Nombela-Franco L, Webb JG, de Jaegere PP, Toggweiler S, Nuis R-J, Dager AE, et al. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation. 2012;126(25):3041–53. Observational multicenter study providing important insights into the occurence of cerebrovascular events after TAVI.

52.

Nuis R-J, Van Mieghem NM, Schultz CJ, Moelker A, van der Boon RM, van Geuns RJ, et al. Frequency and causes of stroke during or after transcatheter aortic valve implantation. Am J Cardiol. 2012;109(11):1637–43.PubMedCrossRef

53.

Eggebrecht H, Schmermund A, Voigtländer T, Kahlert P, Erbel R, Mehta RH. Risk of stroke after transcatheter aortic valve implantation (TAVI): a meta-analysis of 10,037 published patients. EuroIntervention. 2012;8(1):129–38.PubMedCrossRef

54.

Motloch LJ, Reda S, Rottlaender D, Khatib R, Müller-Ehmsen J, Seck C, et al. Postprocedural atrial fibrillation after transcatheter aortic valve implantation versus surgical aortic valve replacement. Ann Thorac Surg. 2012;93(1):124–31.PubMedCrossRef

55.

Stortecky S, Buellesfeld L, Wenaweser P, Heg D, Pilgrim T, Khattab AA, et al. Atrial fibrillation and aortic stenosis: impact on clinical outcomes among patients undergoing transcatheter aortic valve implantation. Circ Cardiovasc Interv. 2013;6(1):77–84.PubMedCrossRef

56.

Salinas P, Moreno R, Calvo L, Jiménez-Valero S, Galeote G, Sánchez-Recalde A, et al. Clinical and prognostic implications of atrial fibrillation in patients undergoing transcatheter aortic valve implantation. World J Cardiol. 2012;4(1):8–14.PubMedCentralPubMed

57.•

Amat-Santos IJ, Rodés-Cabau J, Urena M, DeLarochellière R, Doyle D, Bagur R, et al. Incidence, predictive factors, and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation. J Am Coll Cardiol. 2012;59(2):178–88. Comprehensive observational study on the occurence of new onset atrial fibrillation after TAVI.

58.•

Rodés-Cabau J, Dauerman HL, Cohen MG, Mehran R, Small EM, Smyth SS, e.a. Antithrombotic Treatment in Transcatheter Aortic Valve Implantation: Insights for Cerebrovascular and Bleeding Events. J Am Coll Cardiol. 2013. doi:10.1016/j.jacc.2013.03.029. Consensus document on the current status of cerebrovascular and bleeding events after TAVI and the possible implications for antithrombotic treatment.

59.

Treede H, Mohr F-W, Baldus S, Rastan A, Ensminger S, Arnold M, et al. Transapical transcatheter aortic valve implantation using the JenaValve™ system: acute and 30-day results of the multicentre CE-mark study. Eur J Cardiothorac Surg. 2012;41(6):e131–8.PubMedCrossRef

60.

Treede H, Tübler T, Reichenspurner H, Grube E, Pascotto A, Franzen O, et al. Six-month results of a repositionable and retrievable pericardial valve for transcatheter aortic valve replacement: the Direct Flow Medical aortic valve. J Thorac Cardiovasc Surg. 2010;140(4):897–903.PubMedCrossRef

61.

Gooley R, Lockwood S, Antonis P, Meredith IT. The SADRA Lotus Valve System: a fully repositionable, retrievable prosthesis. Minerva Cardioangiol. 2013;61(1):45–52.PubMed

62.

Willson AB, Rodès-Cabau J, Wood DA, Leipsic J, Cheung A, Toggweiler S, et al. Transcatheter aortic valve replacement with the St. Jude Medical Portico valve: first-in-human experience. J Am Coll Cardiol. 2012;60(7):581–6.PubMedCrossRef

63.

Binder RK, Rodés-Cabau J, Wood DA, Mok M, Leipsic J, De Larochellière R, et al. Transcatheter aortic valve replacement with the SAPIEN 3: a new balloon-expandable transcatheter heart valve. JACC Cardiovasc Interv. 2013;6(3):293–300.PubMedCrossRef

64.

Falk V, Walther T, Schwammenthal E, Strauch J, Aicher D, Wahlers T, et al. Transapical aortic valve implantation with a self-expanding anatomically oriented valve. Eur Heart J. 2011;32(7):878–87.PubMedCrossRef

65.

Schultz CJ, Moelker A, Piazza N, Tzikas A, Otten A, Nuis RJ, et al. Three dimensional evaluation of the aortic annulus using multislice computer tomography: are manufacturer’s guidelines for sizing for percutaneous aortic valve replacement helpful? Eur Heart J. 2010;31(7):849–56.PubMedCrossRef

66.

Binder RK, Webb JG, Willson AB, Urena M, Hansson NC, Norgaard BL, e.a. The impact of integration of a multidetector computed tomography annulus area sizing algorithm on outcomes of transcatheter aortic valve replacement: a prospective, multicenter, controlled trial. J Am Coll Cardiol. 2013;62(5):431–8.

67.

de Vaan J, Verstraeten L, de Jaegere P, Schultz C. The 3mensio Valves™ multimodality workstation. EuroIntervention. 2012;7(12):1464–9.PubMedCrossRef

68.

Grube E, Naber C, Abizaid A, Sousa E, Mendiz O, Lemos P, et al. Feasibility of transcatheter aortic valve implantation without balloon pre-dilation: a pilot study. JACC Cardiovasc Interv. 2011;4(7):751–7.PubMedCrossRef

69.

Van Mieghem NM, Schipper MEI, Ladich E, Faqiri E, van der Boon R, Randjgari A, et al. Histopathology of embolic debris captured during transcatheter aortic valve replacement. Circulation. 2013;127(22):2194–201.PubMedCrossRef

70.

Dvir D, Lavi I, Eltchaninoff H, Himbert D, Almagor Y, Descoutures F, et al. Multicenter evaluation of Edwards SAPIEN positioning during transcatheter aortic valve implantation with correlates for device movement during final deployment. JACC Cardiovasc Interv. 2012;5(5):563–70.PubMedCrossRef

71.

Tchetche D, Modine T, Farah B, Vahdat O, Sudre A, Koussa M, et al. Update on the need for a permanent pacemaker after transcatheter aortic valve implantation using the CoreValve® Accutrak™ system. EuroIntervention. 2012;8(5):556–62.PubMedCrossRef

72.

Muñoz-García AJ, Hernández-García JM, Jiménez-Navarro MF, Alonso-Briales JH, Domínguez-Franco AJ, Fernández-Pastor J, et al. Factors predicting and having an impact on the need for a permanent pacemaker after CoreValve prosthesis implantation using the new Accutrak delivery catheter system. JACC Cardiovasc Interv. 2012;5(5):533–9.PubMedCrossRef

Title: Clinical Implications of Conduction Abnormalities and Arrhythmias After Transcatheter Aortic Valve Implantation
Authors: Robert M. A. van der Boon
Patrick Houthuizen
Rutger-Jan Nuis
Nicolas M. van Mieghem
Frits Prinzen
Peter P. T. de Jaegere
Publication date: 01-01-2014
Publisher: Springer US
Published in: Current Cardiology Reports / Issue 1/2014
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-013-0429-4

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinical Implications of Conduction Abnormalities and Arrhythmias After Transcatheter Aortic Valve Implantation

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Guidance of Transcatheter Aortic Valve Replacement by Echocardiography

Incremental Value of 3-D Transesophageal Echocardiographic Imaging of the Mitral Valve

Percutaneous Mitral Valve Repair

Artificial Intelligence in Medicine and Cardiac Imaging: Harnessing Big Data and Advanced Computing to Provide Personalized Medical Diagnosis and Treatment

Bleeding Risk Prediction Models in Atrial Fibrillation

Guidance of Treatment of Perivalvular Prosthetic Leaks

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page